Sutro Biopharma, Inc.

Jeffrey Hanson

Ryan Stafford

Gang Yin

Alice Yam

Xiaofan Li

Cristina Abrahams

Krishna Bajjuri

Daniel Calarese

Andreas Maderna

Abigail Yu

Amandeep Gakhal

Miao Wen

Helena Kiefel

Kristin Bedard

Daniel Groff

This disclosure provides a method of producing full-length antibodies inwith a yield of at least about 200 mg/L. Thecells typically have an oxidative cytoplasm, which is helpful for maintaining the three-dimensional structure and stability of proteins having disulfide bonds. In some cases, the molar ratio of the produced HC and LC amount from culturing theranges from about 1:1 to about 1:3 (e.g., from about 1:1 to about 1:2.5, from about 1:1 to about 1:2).

Methods of producing full-length antibodies using

The present disclosure relates to antibodies and antibody conjugates, for instance antibody drug conjugates, with binding specificity for receptor tyrosine kinase orphan receptor 1 (ROR1) and its isoforms and homologs, and compositions comprising the antibodies or antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibodies and antibody conjugates and compositions thereof as well as methods of using the antibodies and antibody conjugates and compositions thereof, such as in therapeutic and diagnostic methods.

Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class

Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates

Growing community of inventors

Oakland, CA, United States of America

Jeffrey Hanson